Illinois Tool Works, Wynn Resorts, Agree Realty, Crispr Therapeutics, Super Micro Computer: Trending by Analysts
Crispr Therapeutics Is Maintained at Equal-Weight by Barclays
Crispr Therapeutics Price Target Cut to $42.00/Share From $56.00 by Barclays
Barclays Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Cuts Target Price to $42
Express News | CRISPR Therapeutics AG : Barclays Cuts Target Price to $42 From $56
Truist Financial Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
BMO Capital Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Cuts Target Price to $75
Express News | Goldman Sachs Maintains Neutral on CRISPR Therapeutics, Lowers Price Target to $47
BMO Capital Sticks to Their Buy Rating for Crispr Therapeutics AG (CRSP)
A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $38 to $105
Beware of Sarepta, CRISPR Therapeutics, and More
CRISPR Therapeutics Reports Q1 2025 Progress and Financials
Cathie Wood's ARK Investment Buys 329K Shares of Crispr Therapeutics Today
CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
Crispr Therapeutics Is Maintained at Buy by Needham
These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results
Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday
CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks
RBC Capital Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP)